Other languages Johnson & Johnson BOERSE MUENCHEN

Equities

JNJ

US4781601046

Real-time BOERSE MUENCHEN Other stock markets 08:25:46 28/06/2024 pm IST			5-day change	1st Jan Change
136.6 ^EUR	+0.26%		-1.39%	-3.80%

08:00am	Dealmakers optimistic on global M&A prospects despite sluggish growth	RE
27/06	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Dealmakers optimistic on global M&A prospects despite sluggish growth	11:30am
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	24/06
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06
Johnson & Johnson : dossier déposé dans la maladie de Crohn	21/06
Johnson & Johnson : le rachat de Proteologix est bouclé	21/06
Johnson & Johnson Completes Acquisition of Proteologix	21/06
Johnson & Johnson Completes Acquisition of Proteologix	21/06
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	21/06
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	21/06
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	21/06
J&J : lance un écosystème numérique ouvert et sécurisé	20/06
J&J : des résultats prometteurs dans la maladie de Crohn	20/06
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	20/06
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	20/06
J&J : sollicite la FDA dans le cancer du poumon	17/06
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	17/06
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	17/06
J&J : résultat positif dans la maladie de Sjögren	17/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST